Clinical Trial Update: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating niraparib and dostarlimab for small cell lung cancer and other high-grade neuroendocrine carcinomas; the trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Small Cell Carcinoma, Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING